Introduction {#Sec1}
============

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the population over the age of 50 years in the developed world \[[@CR1], [@CR2]\]. The exudative, neovascular form of the disease usually results in rapid loss of vision \[[@CR3]\]. The intravitreal use of recombinant, humanized, monoclonal antibodies Fab to neutralize all active forms of vascular endothelial growth factor A (VEGF-A) such as ranibizumab (Lucentis; Genetech, San Francisco, CA; and Novartis, West Sussex, UK) and bevacizumab (Avastin; Roche and Genentech, Basel, Switzerland) revolutionised AMD therapy and has provided significant benefits with respect to the anatomic and visual acuity (VA) outcomes as demonstrated in the MARINA and ANCHOR studies \[[@CR4], [@CR5]\]. A further 2008 Cochrane systematic review concluded that ranibizumab therapy was beneficial for the treatment of AMD and associated with relatively few adverse effects \[[@CR6]\]. The ANCHOR and MARINA trials demonstrated that between 94.3% and 94.6% of patients treated with ranibizumab maintained vision at 12 months (loss of fewer than 15 letters) compared to 62.2% on placebo. Moreover, visual acuity improved by more than 15 letters in 24.8--40.3% of patients who received ranibizumab compared to only 5.0% in the placebo control group \[[@CR4], [@CR5]\].

Although this represents a satisfactory treatment response, approximately 5% of this group experienced significant deterioration in visual acuity (loss of more than 15 letters at 12 months) \[[@CR4], [@CR5]\]. The percentage of participants who experienced deterioration in visual acuity increased to approximately 10% at 24 months \[[@CR7]\]. The CATT study reported similar visual acuity outcomes after 1 and 2 years for ranibizumab and bevacizumab under the same treatment protocol \[[@CR8]\]. Importantly, persistent macular fluid was detected by optical coherence tomography (OCT) in 51.5% of the patients treated with monthly ranibizumab and 67.4% of those treated with monthly bevacizumab injections after 2 years. These rates were even higher when the pro re nata (PRN) protocol was used \[[@CR8]\]. In addition, a reduction in visual acuity of more than 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters at 2 years was reported in 6.7% and 7.2% of patients treated with monthly and PRN ranibizumab respectively. The respective percentages for the bevacizumab group were 7.8% (monthly) and 11.6% (PRN) \[[@CR8]\].

Several studies have investigated the predictive value of clinical and genetic factors in the treatment response. A poorer treatment outcome has been associated with greater age, better baseline VA, larger choroidal neovascularisation (CNV) lesion at baseline and a greater interval between onset of symptoms and initiation of treatment \[[@CR9]\]. Moreover, extensive research has been performed to identify genetic associations with response to anti-VEGF therapies but the results are as yet inconclusive \[[@CR10]\].

The subgroup showing resistant or refractory AMD is expected to incur significant morbidity and therefore specific research of alternative therapeutic regimens to improve outcomes is warranted. In addition to significant morbidity, AMD bears significant socioeconomic implications through direct and indirect medical and social cost \[[@CR11], [@CR12]\], loss of earnings, loss of healthy life \[[@CR13]\] and a significant reduction in vision-related quality of life (VRQoL) \[[@CR14], [@CR15]\]. Conversely, a subsequent improvement in visual acuity is shown to be associated with improved functioning and quality of life \[[@CR16]\].

A number of studies investigating the therapeutic potential of aflibercept, a recombinant soluble decoy receptor fusion protein with a greater affinity for VEGF-A, VEGF-B and placental growth factor \[[@CR17]\], have been conducted. VIEW 1 and VIEW 2 multicentre studies assessed the efficacy and safety of aflibercept \[[@CR18]\]. Various aflibercept treatment regimens have been used to optimise the AMD treatment and more recently some studies have investigated the potential of this therapy specifically in recalcitrant nAMD. The aim of this article was to critically review the success of switching from the other two antiangiogenic agents to aflibercept in individuals with refractory or recurrent AMD.

Methods {#Sec2}
=======

We searched Cochrane Library and MEDLINE for publications related to the review objective. Our search strategy consisted of subject headings and keywords 'wet macular degeneration', 'angiogenesis inhibitors', 'aflibercept', 'VEGF trap', 'bevacizumab', 'ranibizumab', 'switch', 'refractory', 'resistant', 'transition' and 'recalcitrant'. Databases were last searched in August 2018.

Search results were analysed by title and abstract to determine their relevance to the review objective. Publications were included in the analysis if participants had a diagnosis of wet, neovascular or exudative AMD, previously treated with intravitreal injections of 0.5 mg ranibizumab, 1.25 mg bevacizumab or both, who were switched to treatment with aflibercept because of persistent intraretinal or subretinal fluid as determined by OCT. Exclusion criteria included a sample size of smaller than ten eyes and a follow-up period of less than 6 months. Only studies published in English were included.

Data collected from the publications included date of publication, study design, number of participants, inclusion/exclusion criteria of the study, intervention protocol, mean injection frequency, follow-up period, visual acuity and anatomical outcomes. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec3}
=======

Our search yielded 66 studies relevant to our review objective, published between July 2013 and August 2018. Twenty-one publications were excluded from our analysis: 5 publications were review articles, 3 publications had a small sample size and 13 publications did not have a sufficient follow-up period. The remaining 45 publications were included in our data analysis. A summary of the results of our search and data collection is shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1List of prospective studies included in this reviewStudySample sizeFollow-up (months)Previous anti-VEGF treatmentReason for switchResultsOutcome measureChange1Aghdam et al. \[[@CR20]\]2212RanibizumabPersistent IRF and/or SRFBCVAFrom 45 to 59 letters (*p* \< 0.001)CSTFrom 400 to 304 µm (*p* = 0.003)CNV areaFrom 0.38 to 0.28 mm^2^ (*p* = 0.003)2Blanco-Garavito et al. \[[@CR25]\]848RanibizumabPersistent PED (height \> 250 µm)BCVAFrom 66.2 to 69.5 letters (*p* = 0.003)CMTFrom 444 to 387 (*p* \< 0.001)PED heightFrom 347 to 288 (*p* \< 0.001)3Chang et al. \[[@CR22]\]4912Ranibizumab and/or bevacizumabPersistent IRF or SRFBCVA+ 4.7 letters (*p* \< 0.001)CRT− 97.2 µm (*p* \< 0.001)4Curry et al. \[[@CR24]\]1912RanibizumabPersistent SRF or cystoid edemaBCVA+ 6 letters (*p* = 0.04)CMTFrom 268 to 255 µm (*p* = 0.018)5Grewal et al. \[[@CR28]\]2112Ranibizumab or bevacizumabPersistent IRF and/or SRFBCVAFrom 0.42 to 0.40 logMAR (non-significant)CFTFrom 329 to 292 μm (*p* = 0.038)PED basal diameterFrom 2350 to 1856 μm (*p* = 0.028)PED heightFrom 288 to 248 μm (*p* = 0.002)6Jorstad et al. \[[@CR33]\]5024Ranibizumab or bevacizumabPersistent macular fluidBCVAFrom 0.25 to 0.32 logMAR (*p* = 0.005)CRTFrom 273 to 225 µm (*p* \< 0.001)7Kawashima et al. \[[@CR21]\]416RanibizumabRecurrent/residual exudationBCVA− 0.05 logMAR (*p* = 0.013)CRT− 39 µm (*p* = 0.001)PED− 43.9 µm (*p* \< 0.001)8Kim et al. \[[@CR31]\]4012Ranibizumab or bevacizumabRecurrent increase in retinal edema, PED and/or SRFBCVA+ 4.4 letters (non-significant)CST− 42 µm (*p* = 0.001)PED vol− 0.07 mm^3^ (*p* = 0.345)9Mantel et al. \[[@CR32]\]2112RanibizumabRefractory/recurrent IRF/SRFBCVA− 2 letters (non-significant)10Sarao et al. \[[@CR29]\]9212RanibizumabPersistent/recurrent SRF and/or IRFBCVA+ 1.8 letters (*p* \> 0.05)CRT− 112 µm (*p* \< 0.001)11Singh et al. \[[@CR23]\]2612Ranibizumab and/or bevacizumabRecurrent IRF/SRF/cystoid fluid or worsening PED or new haemorrhage on clinical examinationBCVA+ 9.2 letters (*p* \< 0.001)CST− 50.2 μm (*p* \< 0.001)12Sleiman \[[@CR30]\]176RanibizumabPersistent SRF/IRFBCVAFrom 0.998 to 0.933 logMARCFTFrom 534 to 356 µm13Tiosano et al. \[[@CR19]\]476BevacizumabIRF/SRF and/or PED height \> 300 µmBCVAFrom 60.3 to 63.1 letters (*p* = 0.02)CSTFrom 409 to 277 µm (*p* = 0.0002)14Wykoff et al. \[[@CR27]\]466RanibizumabRecalcitrant wet AMDBCVA+ 0.2 letters (non-significant)CST− 23.6 µm (*p* = 0.018)15Zhu et al. \[[@CR26]\]4912Ranibizumab and/or bevacizumabPersistent SRF and/or IRFBCVA+ 4.7 letters (*p* \< 0.001)CMTFrom 448 to 351 µm (*p* \< 0.001)The prospective studies, their main characteristics and results are shown below. The column "Change" refers to the mean change of the respective metric from the time of the switch to the final time point of follow-up*AMD* age-related macular degeneration, *BCVA* best-corrected visual acuity, *CFT* central foveal thickness, *CMT* central macular thickness, *CNV* choroidal neovascularisation, *CRT* central retinal thickness, *CST* central subfield thickness, *IRF* intraretinal fluid, *PED* pigment epithelium detachment, *SRF* subretinal fluidTable 2List of retrospective studies included in this reviewStudySample sizeFollow-up (months)Previous anti-VEGF treatmentReason for switchResultsOutcome measureChange1Arcinue et al. \[[@CR46]\]6312Ranibizumab and/or bevacizumabPersistent or recurrent IRF/SRF/PED/leakage on FABCVA+ 2.5 letters (non-significant)MRTFrom 355 to 248 µm (*p* \< 0.001)2Barthelmes et al. \[[@CR56]\]38412Ranibizumab and/or bevacizumabNot definedBCVAFrom 63.4 to 63.3 letters (*p* = 0.17)3Cardoso et al. \[[@CR61]\]16436Ranibizumab and/or bevacizumabPersistent or recurrent SRF and/or IRF or non-medical departmental reasonsBCVA (12 months)From 56.5 to 54.6 letters (non-significant)CRT (12 months)From 386 to 313 µm (*p* \< 0.001)BCVA (36 months)From 56.5 to 50.3 letters (*p* \< 0.001)CRT (36 months)From 386 to 266 µm (*p* \< 0.001)4Chan et al. \[[@CR34]\]1896Ranibizumab and bevacizumabPersistent/recurrent macular edema, SRF haemorrhage, exudates and/or PEDBCVA− 0.081 logMAR (*p* \< 0.001)CST− 24.9 μm (*p* \< 0.001)PED height− 43.4 μm (*p* \< 0.001)5Chatziralli et al. \[[@CR54]\]44712RanibizumabPersistent SRF/IRF or PED involving the fovea or macular haemorrhageBCVAFrom 63.7 to 63.3 letters (non-significant)CSTFrom 271 to 242 μm (*p* \< 0.001)6Cho et al. \[[@CR40]\]286Ranibizumab and/or bevacizumabPersistent fluidBCVAFrom 0.52 to 0.57 logMAR (non-significant)CRTFrom 294 to 275 μm (*p* = 0.008)7De Massougnes et al. \[[@CR47]\]609RanibizumabPersistent IRF/SRFBCVAFrom 73 to 74 letters (non-significant)CSTFrom 372 to 321 μm (*p* \< 0.001)8Dirani et al. \[[@CR53]\]9812RanibizumabPersistent IRF/SRFBCVAFrom 72.1 to 71.9 letters (non-significant)CRT349 to 300 μm9Ferrone et al. \[[@CR59]\]2216Ranibizumab and bevacizumabNo criteriaBCVAFrom 0.506 to 0.521 logMAR (non-significant)CRTFrom 261 to 237 μm (*p* = 0.012)10Gharbiya et al. \[[@CR42]\]316RanibizumabPersistent IRF/SRFwith/without PEDBCVAFrom 42.5 to 42.8 letters (non-significant)CSTFrom 449 to 269 μm (*p* \< 0.001)PED heightFrom 262 to 183 μm (*p* \< 0.001)CTFrom 192 to 167 μm (*p* \< 0.001)11Hall et al. \[[@CR43]\]3012Ranibizumab and/or bevacizumabNo criteriaBCVAFrom 0.506 to 0.521 (non-significant)CMTFrom 261 to 237 μm (*p* = 0.012)12Hirakata et al. \[[@CR36]\]1412RanibizumabNo improvement or recurrence on OCTBCVAFrom 0.4 to 0.32 logMAR (*p* = 0.018)CMTFrom 273 to 208 μm (*p* = 0.002)13Homer et al. \[[@CR58]\]2124Ranibizumab and bevacizumabPersistent exudationBCVAFrom 0.42 to 0.42 logMAR (non-significant)CSTFrom 292 to 283 μm (non-significant)MTIFrom 37 to 57.4 days (*p* = 0.01)14Kanesa-Thasan et al. \[[@CR55]\]1118RanibizumabRecalcitrant PEDBCVAFrom 63.7 to 63.3 letters (non-significant)PED volFrom 0.687 to 0.652 mm^3^ (*p* = 0.02)15Kocak \[[@CR38]\]1512RanibizumabIRF, SRF, haemorrhage or \< 10% decrease in PED height or radiusBCVAFrom 0.63 to 0.43 (*p* = 0.0049)PED heightFrom 297 to 122 μm (*p* = 0.0007)PED radiusFrom 2371 to 1859 μm (*p* = 0.0007)16Kumar et al. \[[@CR35]\]346RanibizumabPersisting SRF and/or IRFBCVAFrom 0.57 to 0.47 logMAR (*p* = 0.004)CFTFrom 416 to 248 μm (*p* \< 0.001)PED heightFrom 260 to 214 μm (*p* \< 0.001)PED diameterFrom 3265 to 2949 μm (*p* = 0.04)17Lee et al. \[[@CR62]\]13446RanibizumabNo criteriaBCVASignificant improvement at 2, 3 and 5 months but not 618Messenger et al. \[[@CR44]\]10912Ranibizumab and/or bevacizumabNo criteria (physician's discretion)BCVAFrom 0.506 to 0.51 logMAR (non-significant)CSTFrom 324 to 299 μm (*p* = 0.0047)NOI/yearFrom 7.4 to 7.2 (non-significant)19Moon et al. \[[@CR60]\]326RanibizumabPersistent/recurrent fluid OCT or leakage on FABCVAFrom 0.81 to 0.81 logMAR (non-significant)CMTFrom 321 to 327 μm (non-significant)20Muftuoglu et al. \[[@CR48]\]8124Ranibizumab or bevacizumabPersistent/recurrent IRF/SRF or leakageBCVAFrom 0.55 to 0.56 logMAR (non-significant)CMTSignificant reduction (*p* \< 0.001)21Narayan et al. \[[@CR39]\]19216RanibizumabPersistent macular fluid or required 4- or 6-week injection intervals to maintain a fluid-free maculaBCVA+ 4.5 letters (*p* = 0.0003)22Nomura et al. \[[@CR65]\]2512RanibizumabNo specific criteria (physician's discretion)BCVACVH(−): From 0.32 to 0.14 logMAR (*p* = 0.0001)CVH(+): From 0.21 to 0.19 logMAR (non-significant)CRTCVH(−): From 273 to 161 μm (*p* \< 0.0002)CVH(+): From 316 to 157 μm (*p* = 0.0037)23Pinheiro-Costa et al. \[[@CR45]\]8512Ranibizumab and/or bevacizumabPersistent/recurrent IRF/SRFBCVA− 2 letters (non-significant)CRTFrom 375 to 295 μm (*p* \< 0.001)NOIFrom 0.57 to 0.76 (*p* \< 0.001)24Ricci et al. \[[@CR49]\]7212RanibizumabPersistent IRF/SRFBCVAFrom 64 to 67 letters (non-significant)CMTFrom 403 to 266 μm (non-significant)25Thorell et al. \[[@CR41]\]736Ranibizumab or bevacizumabFrequent re-treatmentBCVAFrom 69 to 69.5 letters (non-significant)CRT− 19 μm (*p* \< 0.001)NOI− 0.6 (*p* \< 0.001)26Tyagi et al. \[[@CR57]\]5012RanibizumabInadequate anatomical/functional responseBCVA+ 1.16 letters (non-significant)PED height− 50.64 μm (*p* = 0.007)PED width+ 29.7 μm (non-significant)27Waizel et al. \[[@CR51]\]96\> 6BevacizumabPersisting/increasing SRF/IRF or internal non-medical policy decisionsBCVAFrom 0.63 to 0.53 logMAR (non-significant)CMTFrom 419 to 318 μm (*p* \< 0.0001)28Warwick et al. \[[@CR37]\]10712Ranibizumab or bevacizumabPoor OCT and visual responseBCVA+ 3.28 letters (p = 0.0005)CRT− 6.16 (*p* \< 0.001)29You et al. \[[@CR52]\]3316Ranibizumab or bevacizumabPersistent/recurrent exudationBCVAFrom 55.3 to 57.8 letters (non-significant)CFTFrom 302 to 241 μm (*p* = 0.001)PED height− 109.8 (*p* = 0.02)30Van Lancker et al. \[[@CR50]\]6814--38RanibizumabPersisting SRF/IRFBCVAFrom 0.57 to 0.54 logMAR (non-significant)CRT− 75.6 (*p* = 0.001)The retrospective studies, their main characteristics and results are shown here. The column "Change" refers to the mean change of the respective metric from the time of the switch to the final time point of follow-up*AMD* age-related macular degeneration, *BCVA* best-corrected visual acuity, *CFT* central foveal thickness, *CMT* central macular thickness, *CNV* choroidal neovascularisation, *CRT* central retinal thickness, *CST* central subfield thickness, *CVH* choroidal vascular hyperpermeability, *IRF* intraretinal fluid, *MRT* maximum retinal thickness, *MTI* mean treatment interval, *NOI* number of injections, *PED* pigment epithelium detachment, *SRF* subretinal fluid

Fifteen out of the 45 included studies were prospective; three of them were multicentre single-arm and one of them was a single-centre randomised with control arm. The remaining 30 were retrospective studies, one of which was a multicentre electronic medical record (EMR) review with control arm.

The inclusion and exclusion criteria for participants of the 45 studies displayed a significant degree of heterogeneity. Studies lacked a clear consensus regarding baseline participant features such as participant age, baseline visual acuity, persistent or refractory subretinal fluid, bilateral or unilateral AMD, previous intervention frequency and duration and the presence or absence of additional retinal pathology including pigment epithelial detachment (PED), subretinal fibrosis, geographic atrophy, idiopathic polypoidal choroidal vasculopathy, central serous retinopathy or cystic degeneration. In most studies performed to date refractory status was defined by the presence of intra- or subretinal fluid (IRF, SRF) and/or pigment epithelium detachment (PED), with or without macular haemorrhage despite regular treatment. The switch to aflibercept was carried out after 3--9 anti-VEGF (bevacizumab and/or ranibizumab) intravitreal injections, which were performed within a period of 3--12 months. The intervals between the last anti-VEGF injection and the first aflibercept injection was no longer than 6 weeks.

Prospective Studies {#Sec4}
-------------------

Several clinical trials have assessed the efficacy of switching to aflibercept in nAMD patients following unsatisfactory response to prior therapy (Table [1](#Tab1){ref-type="table"}). In a multicentre prospective study, Tiosano et al. \[[@CR19]\] studied 47 eyes from 46 nAMD patients with incomplete response to bevacizumab. Twenty-eight weeks after switching to aflibercept therapy, the mean best corrected visual acuity (BCVA) showed mild but statistical significant improvement from 60.3 to 63.1 EDTRS letters (*p* = 0.02), while the central subfield thickness (CST) was significantly reduced from 409 to 277 µm (*p* = 0.0002) \[[@CR19]\]. When switching patients from ranibizumab to aflibercept, Aghdam et al. \[[@CR20]\] found a significant mean BCVA increase from 45 to 59 EDTRS letters (*p* \< 0.001) after 12 months follow-up in 22 eyes (19 patients) with nAMD. The CST was also significantly reduced from 400 to 304 µm (*p* = 0.003). Similarly, Kawashima et al. \[[@CR21]\], Chang et al. \[[@CR22]\], Singh et al. \[[@CR23]\], Curry et al. \[[@CR24]\], Blanco-Garavito et al. \[[@CR25]\] and Zhu et al. \[[@CR26]\] have demonstrated a statistically significant improvement in both BCVA and CRT following switching from ranibizumab and/or bevacizumab to aflibercept for the treatment of refractory nAMD.

In contrast, a number of studies have failed to record a significant improvement in terms of visual acuity when switching to aflibercept therapy despite identifying a significant improvement in terms of central retinal thickness (CRT). More specifically, Wykoff et al. \[[@CR27]\] prospectively studied patients with recalcitrant nAMD initially treated with ranibizumab. Six months after switching to aflibercept therapy, there was a significant reduction of 23.6 µm in the CST (*p* = 0.018) but BCVA did not improve \[[@CR27]\]. No significant gain in BCVA has been reported in four other studies, despite the significant CRT reduction \[[@CR28]--[@CR31]\].

It is worth noting that to date the only prospective randomised clinical trial with a control arm was conducted by Mantel et al. \[[@CR32]\]. This small study included 21 eyes (19 patients) that had been treated with ranibizumab and still required monthly injections at the end of the second year of treatment. These patients were randomised to either continue ranibizumab injections or switch to aflibercept. After 12 months, the BCVA change was not found to be significantly different between the two groups. In addition, the mean retreatment interval was 1.13 months in the aflibercept group and 1.14 months in the control group \[[@CR32]\].

Jorstad et al. \[[@CR33]\] evaluated prospectively the efficacy of switching from bevacizumab or ranibizumab to aflibercept in 50 eyes from 47 nAMD patients with persistent macular fluid. Notably, these authors reported a statistically significant reduction in BCVA after 2 years of follow-up, from 0.25 to 0.32 logMAR (*p* = 0.005), even though no significant difference was detected during the first year (0.24 logMAR) \[[@CR33]\].

Retrospective Evidence {#Sec5}
----------------------

A large number of retrospective studies have evaluated the outcomes of transition to aflibercept therapy in nAMD (Table [2](#Tab2){ref-type="table"}). Chan et al. \[[@CR34]\] included 189 cases, the majority of which (82%) were refractory to bevacizumab and ranibizumab injections. They documented a significant improvement in BCVA of 0.081 logMAR (*p* \< 0.001) and a significant reduction in CST of 24.9 μm (*p* \< 0.001) after 6 months \[[@CR34]\]. Further statistically significant improvements of BCVA and CRT were also reported in other studies \[[@CR35]--[@CR38]\]. Narayan et al. \[[@CR39]\] found a significant BCVA improvement in patients with refractory to ranibizumab therapy but with no CRT data.

In contrast, several clinical trials have reported a lack of BCVA improvement despite significantly improved anatomical outcomes \[[@CR40]--[@CR53]\]. Chatziralli et al. \[[@CR54]\] reported the results of large retrospective study which included 447 eyes with persistent nAMD despite treatment with ranibizumab injections. Twelve months after switching to aflibercept, the BCVA did not change (from 63.7 to 63.3 ETDRS letters), although the CST was significantly reduced from 271 to 242 μm (*p* \< 0.001) \[[@CR54]\]. Moreover, a non-significant VA change without any CRT data was reported by Kanesa-Thasan et al. \[[@CR55]\], Barthelmes et al. \[[@CR56]\] and Tyagi et al. \[[@CR57]\].

Homer et al. \[[@CR58]\] reported an unchanged BCVA (from 0.42 to 0.42 logMAR) and a small, non-significant reduction of CST (from 292 to 283 μm) in a small cohort of 21 eyes with persistent exudation 2 years after converting to aflibercept. Similarly, Ferrone et al. \[[@CR59]\] and Moon et al. \[[@CR60]\] reported non-significant functional and anatomical changes 6 months after the switch.

It is worth noting that a single study reported a significant reduction in terms of BCVA when switching from ranibizumab and/or bevacizumab to aflibercept \[[@CR61]\]. This study demonstrated a significant BCVA reduction, from 56.5 to 50.3 letters (*p* \< 0.001), 3 years after transition to aflibercept in 164 nAMD eyes, although vision was found to be stable 1 year after the switch. Interestingly, CRT was significantly improved at both time points \[[@CR61]\] so one could hypothesize that other factors and the natural course of the disease may account for the ultimate reduction in vision after transition to aflibercept.

The only retrospective study with a control arm was reported by Lee et al. \[[@CR62]\]. It was a multicentre study comparing the outcomes of 448 eyes that were switched to aflibercept after 6 monthly ranibizumab injections as opposed to 896 eyes which continued ranibizumab therapy. Despite an initial improvement in BCVA after switching to aflibercept therapy, this benefit was not detected 6 months after the switch \[[@CR62]\].

Pigment Epithelial Detachment (PED) {#Sec6}
-----------------------------------

In terms of PED characteristics, such as PED height and volume, several studies showed significant improvement when switching to aflibercept \[[@CR21], [@CR25], [@CR28], [@CR34], [@CR38], [@CR42], [@CR52], [@CR55]\]. In contrast, Kim et al. \[[@CR31]\] reported a stable PED volume 12 months after conversion to aflibercept in cases with refractory PED. Tyagi et al. \[[@CR57]\] found a significant reduction in PED height but not PED width in 50 cases, 12 months after switching from ranibizumab to aflibercept.

Number of Injections {#Sec7}
--------------------

With regard to the number of injections, several studies have shown a significant reduction in the number of injections after a therapeutic switch to aflibercept \[[@CR29], [@CR41], [@CR45], [@CR56], [@CR58]\], while others have reported a non-significant change in the overall number of injections \[[@CR32], [@CR44], [@CR53]\]. Sarao et al. \[[@CR29]\] also found an improvement in the mean injection interval, from 5.3 to 13.6 weeks, in a study of 50 cases that were switched from ranibizumab to aflibercept and were followed up for 1 year.

Quality of Life {#Sec8}
---------------

As for the impact of switching intravitreal therapies on quality of life, Zhu et al. \[[@CR26]\] prospectively assessed the changes in vision-related quality of life in 49 patients with refractory nAMD with the use of the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25). The NEI VFQ-25 composite scores improved significantly after 1 year and this improvement correlated with the significant changes in BCVA but not CMT \[[@CR26]\].

Discussion {#Sec9}
==========

Various contributing factors have been implicated in the suboptimal response to anti-VEGF treatment for patients suffering from exudative AMD \[[@CR9], [@CR10]\]. The hypothesis of reduced anti-VEGF efficacy with repeated injections or a form of treatment-related tachyphylaxis may apply and has resulted in switching between anti-VEGF treatments as a logical management step in clinical practice \[[@CR63]\]. Amoaku et al. \[[@CR63]\] proposed a grading system for the response of patients with exudative AMD to anti-VEGF treatment based on functional and morphological criteria. The response was categorized as good, partial poor and no response in terms of visual acuity and OCT parameters including subretinal/intraretinal fluid, pigment epithelial detachment and central retinal thickness. The authors suggested that switching between anti-VEGF agents is justified only when there is evidence of poor or inadequate response in either function or morphology \[[@CR63]\].

Several conclusions regarding the success of switching from ranibizumab or bevacizumab to aflibercept in patients with exudative AMD can be drawn from our review. In terms of visual acuity many studies suggest a meaningful improvement after the switch. However, the only two comparative studies that have been conducted failed to identify a significant visual difference following treatment change as opposed to continuing with the same agent (ranibizumab) \[[@CR32], [@CR62]\]. In addition, a large retrospective study by Lee et al. \[[@CR62]\] demonstrated a significant improvement in terms of VA immediately after switching to aflibercept; however, this improvement was not sustained after 6 months. The authors suggest that this result is due to tachyphylaxis to ranibizumab rather than to superiority of aflibercept. Moreover, Mantel et al. \[[@CR32]\] showed a non-significant deterioration in VA in patients that switched to aflibercept when compared to controls. Long-term visual outcomes do not appear to be more favourable either \[[@CR33], [@CR61]\] but there may be many compounding factors beyond 2 years of follow-up. Jorstad et al. \[[@CR33]\] and Cardoso et al. \[[@CR61]\] found a significant deterioration in VA at 24 and 36 months respectively after switching to aflibercept, despite stability in their 12-month results \[[@CR33], [@CR61]\]. Since there was no control group in either study, the result can probably be attributed to the natural course of the disease rather than to the actual switch to aflibercept.

In contrast, the majority of switch studies show a significant improvement in anatomical outcomes immediately after the switch that has been maintained throughout the follow-up period \[[@CR19], [@CR21]--[@CR29], [@CR31], [@CR33]--[@CR36], [@CR38], [@CR40]--[@CR48], [@CR50]--[@CR55], [@CR59]--[@CR61], [@CR64], [@CR65]\]. Anatomical features including CRT and PED measured by OCT are consistently improved to a significant degree in almost all of the reviewed studies.

In addition, the injection interval appears to be increased or at least remained stable after the switch in all the pertinent studies. Moreover, the only study that assessed the quality of life showed significant improvement as an additional benefit of the therapeutic switch to aflibercept \[[@CR26]\].

Overall most of the studies support the concept of switching to aflibercept in those patients that show an insufficient response to the other anti-VEGF agents based on improved anatomical outcomes, reduction in intraretinal fluid, subretinal fluid, PED and potentially extended injection intervals. Various studies have shown improvement or stabilization of visual outcomes when switching to aflibercept after suboptimal response to the other two anti-VEGF agents. Nevertheless, it should be emphasized that nonrandomised, retrospective case series on switching are difficult and challenging to interpret because of the plethora of technical biases, lack of controls and the presence of confounding factors. Furthermore, the methodological heterogeneity of the studies creates much uncertainty when trying to answer a specific clinical question such as the one dealt with here. However, case series have a place in preliminary investigational research and are informative in understanding potential strategies for optimising patient care.

Furthermore, the lack of subgroup analysis data, AMD phenotype classification and uniform design of the studies makes any interpretation of benefits a challenging task. The absence of comparative arm in most published studies to date makes interpretation of the findings difficult. Regrettably, the two studies with control arms have been either retrospective or underpowered because of a small sample size \[[@CR32], [@CR62]\]. The absence of masking in the interpretation of fundus fluorescein angiograms and optical coherence tomography examinations is also a methodological setback. Moreover, registration of changes in refractive errors and documentation of cataract were absent in most of the studies performed to date. Additionally, overall one has to consider whether optimal timely and sufficient treatment has been provided to patients with refractive AMD and exclude all possible causes of non-response including masking syndromes.

Conclusions {#Sec10}
===========

The present review attempted to critically summarise current evidence and success rate when switching from ranibizumab or bevacizumab to aflibercept patients with exudative AMD. Although there is a significant body of literature reporting variable results, the cumulative evidence suggests that there may be a benefit. Patients with exudative AMD refractory to other anti-VEGF agents may gain substantial benefit from switching to aflibercept in terms of anatomical outcome and interval between injections; however, there is still uncertainty regarding the visual outcome. Adequately powered randomised controlled trials with appropriate controls are required to address the real benefits of the switch between anti-VEGF agents and establish treatment guidelines for better anatomical and functional outcome.
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